Compare Agnico Eagle Mines Ltd (AEM) vs Novartis AG (NVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Novartis AG — how do they compare? Agnico Eagle Mines Ltd trades at $143.12 (market cap $75.10B), while Novartis AG trades at $155.4 (market cap $298.98B). The key difference: Novartis AG is far larger — about 4× Agnico Eagle Mines Ltd's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| AEM | NVS | |
|---|---|---|
Market Cap | $75.10B | $298.98B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $168.62 |
52-Week Low | $116.14 | $113.50 |
Enterprise Value | $72.30B | $339.00B |
Dividend Yield | 1.2% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $150.33, down 2.29% amid a bearish technical signal but maintains strong fundamentals with a 14.59 P/E ratio and 39.46% net margin. Recent quarterly earnings consistently beat estimates, including Q1 2026 EPS of $3.40 versus $3.19 expected. Revenue grew to $11.91B in 2025, while news highlights temporary mining suspension at Barnat pit but affirms long-term growth projects.
Outlook remains positive with a $222.40 analyst consensus target, though risks include operational disruptions and gold price volatility. The stock offers value with robust cash flow and 67.74% buy ratings, but investors should monitor execution of expansion plans amid bearish technical indicators.
Novartis (NVS) trades at $157.03, down 1.79% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $56.67B revenue, 23.92% net margin, and robust cash flow generation. Recent developments include multiple strategic acquisitions and regulatory approvals expanding the oncology pipeline, though earnings have shown volatility with two misses in the last four quarters.
NVS presents a balanced investment case with strong profitability and pipeline expansion offset by valuation concerns and earnings inconsistency. The stock offers stability through defensive healthcare exposure but faces execution risks from integration challenges and competitive pressures in pharmaceutical markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
